Last update :
03/05/2024
InfoStab
Infostab
List of drugs
List of drugs
Summary lists
Summary lists
Search for compatibilities
Search for compatibilities
Y-site compatibility table
Y-site compatibility table
References
References
Research teams
Research teams
Valistab
Valistab
Poster
Poster
Links
Links
Sponsors
Sponsors
Authors
Authors
User’s guide
User’s guide
Newsletter
Newsletter
Anticancer drug   Vinblastine sulfate  
Injection
Stability in solutions Stability of mixtures Factors which affect stability Compatibility Route of administration References Pdf
   Chemical structure  

Tradename   Tradename     

Trade names are indicative and excipients composition can be different depending on the country and manufacturers
Blestinib Mexico
Cytoblastin Egypt, Malaysia
Lemblastine Chile, Colombia, Mexico
Oncoblastin Colombia
Uniblastin Peru
VBlastin India
Velbe Australia, Austria, Chile, Denmark, Finland, France, Great Britain, Greece, Italy, Luxembourg, Morocco, Netherlands, Norway, Saudi Arabia, Sweden, Switzerland, United Arab Emirates
Velblastin Egypt, Malaysia
Vinblasine Luxembourg
Vinblastin Hungary, Poland
Vinblastina Argentina, Chile, Colombia, Ecuador, Mexico, Peru, Romania, Spain
Vinblastine Australia, Belgium, Canada, France, Great Britain, Iran, Ireland, Netherlands, New Zealand, Saudi Arabia, Tunisia, United States of America
Vinblastinsulfat Germany
Vinblatine Malaysia
Vinko Turkey
Stability in solutions   Injection   Stability in solutions : Vinblastine sulfate     
Container Solvent Concentration Temperature Storage Duration of stability References
Glass Water for Injection 1 mg/ml 4°C Protect from light
21 Day
481
Level of evidence B
Glass Sodium chloride 0,9% 0,05 mg/ml 2-8°C Protect from light
21 Day
1727
Level of evidence C
Glass Sodium chloride 0,9% 0,05 mg/ml 21-25°C Protect from light
21 Day
1727
Level of evidence C
Polyvinyl chloride NaCl 0,9% or Glucose 5% 0,1 mg/ml 4°C Protect from light
7 Day
144
Level of evidence D
Polypropylene NaCl 0,9% or Glucose 5% 0,02 mg/ml 25°C Protect from light
21 Day
481
Level of evidence B
Polypropylene NaCl 0,9% or Glucose 5% 0,02 mg/ml 4°C Protect from light
21 Day
481
Level of evidence B
Polypropylene Ringer’s lactate solution 0,02 mg/ml 25°C Protect from light
21 Day
481
Level of evidence B
Polypropylene Ringer’s lactate solution 0,02 mg/ml 4°C Protect from light
21 Day
481
Level of evidence B
Polypropylen Syringe Water for Injection 1 mg/ml 21°C Protect from light
30 Day
1229
Level of evidence C
Polypropylen Syringe Water for Injection 1 mg/ml 6°C-9°C Protect from light
30 Day
1229
Level of evidence C
  Mentions Légales